Dual-Hormone Systems (Bionic Pancreas)
Current AID systems only deliver insulin (to lower glucose). A true bionic pancreas must also deliver glucagon (to raise it). The iLet Bionic Pancreas currently exists as an insulin-only device, but the architecture is designed for dual-chamber operation once liquid-stable glucagon clears regulatory hurdles.
| Technology | Engineering Challenge | Expected Timeline |
|---|---|---|
| Stable Glucagon | Fibrillation in liquid state | 1-3 Years |
| Optical/Non-Invasive CGM | Signal-to-noise ratio in sweat/skin | 5+ Years (for medical grade) |
| Smart Insulin (Glucose Responsive) | Molecular binding thresholds | 10+ Years |
Non-Invasive Sensing (Optical/Raman Spectroscopy)
Consumer tech companies (Apple, Samsung) are researching optical sensors to measure glucose via light scattering through the skin. While these may provide trend data for wellness, achieving the MARD required to drive a pump safely is physically restricted by the noise of hydration, skin tone, and temperature. Subcutaneous CGM will remain the medical standard.
Ultra-Rapid Analogues
The bottleneck in DIY and commercial systems is insulin kinetics. Fiasp and Lyumjev added niacinamide and citrate to speed up absorption. Future analogues aim for a 5-minute onset, which would allow algorithms to eliminate carb counting entirely.
FAQ
- Will the Apple Watch measure my blood sugar?
- Not accurately enough for dosing insulin. It may provide trend data, but cannot replace a Dexcom or Libre for clinical safety.
- When will we have a cure?
- Stem cell encapsulation (like Vertex VX-880) is making clinical progress, but requires heavy immunosuppression. Until encapsulation materials evade the immune system without drugs, mechanical technology remains the primary treatment.